Shinhan Financial Board Backs KRW 693.3 Billion Cash Purchase Of 77.04% Of Lotte Non-Life Insurance
The closing date is not set, and the price can still change before closing, the company said in a filing.
Shinhan Financial Group's board resolved on Tuesday to buy a 77.04% stake in Lotte Non-Life Insurance for KRW 693,338,632,300 in cash, according to a Form 6-K furnished to the SEC. The deal would make Lotte Non-Life a subsidiary, and it still needs regulatory approval.
What the filing says
The purchase covers 239,082,287 common shares. After it, Shinhan would hold those shares, equal to 77.04% of Lotte Non-Life's total issued shares.
The company put the price at 1.15% of its KRW 60,372,324,867,921 equity capital, based on its consolidated financial statements as of December 31, 2025. It gave the purpose as enhancing the competitiveness of the financial group, for management participation.
The amount can change. The company said the final figure will be confirmed when the transaction closes, and the acquisition date is to be determined, subject to regulatory approval and other procedures.
Lotte Non-Life's numbers
Lotte Non-Life reported net income of KRW 51,331 million for FY2025, versus KRW 24,221 million for FY2024 and KRW 285,581 million for FY2023.
Its total shareholders' equity was KRW 613,504 million at FY2025, down from KRW 794,239 million in FY2024 and KRW 1,301,661 million in FY2023. Total assets were KRW 14,410,299 million and total liabilities KRW 13,796,795 million at FY2025. The filing notes that K-IFRS Standards No. 1109 and No. 1117 have applied since FY2023.
Answer to earlier rumor notices
The filing is the company's final response to two clarification disclosures, filed June 29, 2026 and July 28, 2026, on media reports about a possible Lotte Non-Life deal. Both were classed as undetermined, the second as a re-disclosure.
Shinhan's U.S.-listed shares closed at US$75.21 on Monday, before the announcement, and its market value was US$35.3 billion, according to market data.
The acquisition date depends on regulatory approval, and the price will be fixed only at closing.